DCOMP:NASDAQDime Community Bancshares, Inc. - Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series A Analysis
Data as of 2026-03-28 - not real-time
$18.67
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Dime Community Bancshares (DCOMP) trades around $18.67, delivering a trailing PE of roughly 5×, far below the regional‑bank industry average of 16×. The price‑to‑book ratio of 0.6 and a dividend yield of 7.44% further underscore the stock’s deep discount relative to peers. The balance sheet shows ample liquidity with over $2.4 bn in cash against less than $0.9 bn of debt, resulting in a near‑zero debt‑to‑equity ratio. Operating margins sit near 46% and profit margins at 27%, indicating a profitable core despite modest revenue growth of 1.6%. Recent corporate actions—including a planned name change to “Dime Commercial Bancshares” and a transfer of its listing to the NYSE—signal management’s intent to raise the company’s profile.
Technically, the stock is trading below its 20‑day (18.94), 50‑day (19.16) and 200‑day (19.05) simple moving averages, suggesting short‑term weakness. The RSI of 44.6 and a bearish MACD histogram reinforce a neutral‑to‑bearish momentum bias. Volume has been decreasing, and the 30‑day volatility of about 20% combined with a beta of 0.22 points to low market sensitivity but heightened price swings. Given the strong fundamentals and attractive yield, the valuation leans toward undervalued, while the technicals advise caution in the near term. Consequently, we recommend a hold for the next few weeks, transitioning to a buy stance for medium to long horizons as the price re‑aligns with its intrinsic value.
Technically, the stock is trading below its 20‑day (18.94), 50‑day (19.16) and 200‑day (19.05) simple moving averages, suggesting short‑term weakness. The RSI of 44.6 and a bearish MACD histogram reinforce a neutral‑to‑bearish momentum bias. Volume has been decreasing, and the 30‑day volatility of about 20% combined with a beta of 0.22 points to low market sensitivity but heightened price swings. Given the strong fundamentals and attractive yield, the valuation leans toward undervalued, while the technicals advise caution in the near term. Consequently, we recommend a hold for the next few weeks, transitioning to a buy stance for medium to long horizons as the price re‑aligns with its intrinsic value.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price below key moving averages
- bearish MACD momentum
- decreasing volume
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- significant valuation discount
- high dividend yield
- strong cash position
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- stable earnings margins
- low beta and defensive profile
- strategic rebranding and NYSE listing
Key Metrics & Analysis
Financial Health
Revenue Growth159.40%
Profit Margin27.00%
P/E Ratio5.0
ROE7.71%
ROA0.74%
P/B Ratio0.6
Op. Cash Flow$186.6M
Industry P/E16.0
Technical Analysis
TrendNeutral
RSI44.6
Support$18.13
Resistance$19.50
MA 20$18.94
MA 50$19.16
MA 200$19.05
MACDBearish
VolumeDecreasing
Fear & Greed Index65.98
Valuation
GradeUndervalued
TypeValue
Dividend Yield7.44%
Risk Assessment
Beta0.22
Volatility20.26%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.